Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Gamida Cell -Teva Joint Venture Ltd.
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00469729CT.gov Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Stemex® (this asset) | Gamida Cell -Teva Joint Venture Ltd. | P2/3 | B · 61 |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Camustine | VIVUS LLC | P2 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Vinorelbine Ditartrate | Michael Spinner, MD | P3 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Stemex®
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoid Leukemia | — | P2/3 | B · 61 |
| Chronic Myeloid Leukemia | — | P2/3 | B · 58 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Stemex® in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/stemex-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →